The Injectable Drug Delivery Conference returns live and in person to London in May 2022
Delivery Innovations in Formulation and Device Design for Enhanced Subcutaneous.
- (1888PressRelease) March 15, 2022 - Injectable Drug devices, London, UK
11th May to 12th May 2022,
London, United Kingdom
www.injectable-drug-delivery.com/1888pressrelease
As Part of Europes leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds.
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027.
This years event will highlight the significance of sustainability within the injectable drug delivery industry, whilst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will also highlight successes within the industry and the formulation challenges of long-lasting, highly viscous and high-volume drug delivery. www.injectable-drug-delivery.com/
The benefits of attending:
Discover the new technologies and latest injectable devices being used within the industry
Develop your understanding of high-volume and long-acting injectable compounds
Explore the sustainable possibilities that can be adapted within the industry for a green future
Delve into the world of biologics and biosimilars and what these mean for the injectable drug market
Network with key industry leaders and discover the leading companies within the injectables space
Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
Autoinjectors
Wearables
Device Engineering
Human Factors
CMC
Injectables
Sterile Manufacturing
Packaging
Regulatory Affairs
www.injectable-drug-delivery.com/1888pressrelease
Featured Speakers:
Alexander Zuern, Device testing manager, Novartis International AG
Andrew Warrington, Project Leader & Patient Advocate, Novartis
Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
Bjorg K Hunter, Regulatory Manager, Devices, GSK
Blake Green, Senior Manager Regulatory Affairs, Amgen
Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
Christopher Muenzer, Senior Device Technology Manager, Novartis
Joel Richard, Head of Technical & Pharmaceutical Operations, MedinCell
Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
Rebecca Moses, Director, Core Human Factors Inc.
Rupal Nguyen, Principal Engineer, Allergan
Stefania Ragone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
Tina Arien, Principal Scientist, Janssen Pharmaceutica
Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck
Past attendees have included
Advanz Pharma; Amgen; AstraZeneca; BD - Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierα; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S
www.injectable-drug-delivery.com/1888pressrelease
Additional Contact Info:
T: +44 (0)20 7827 6088
E: rjones ( @ ) smi-online dot co dot uk
LinkedIn: ( @ ) SMi Pharma
Twitter: ( @ ) SMiPharm #SMiInjectables
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam